Literature DB >> 20639617

Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome.

Ricarda M Bauer1, Christian Gratzke, Alexander Roosen, Yasmin Hocaoglu, Margit E Mayer, Alexander Buchner, Christian G Stief, Florian May.   

Abstract

OBJECTIVE: The aim of the study was a prospective assessment of patient-reported side effects in an open-label study after intradetrusor botulinum toxin injections for idiopathic overactive bladder (OAB). PATIENTS AND METHODS: Botulinum toxin A injection was performed in 56 patients with idiopathic OAB. Patients were followed up for 6 months concerning side effects and patients' satisfaction.
RESULTS: Different types of side effects were assessed such as dry mouth (19.6%), arm weakness (8.9%), eyelid weakness (8.9%), leg weakness (7.1%), torso weakness (5.4%), impaired vision (5.4%) and dysphagia (5.4%). In all cases, symptoms were mild and transient. Urological complications such as gross hematuria (17.9%), acute urinary retention (8.9%) and acute urinary tract infection (7.1%) were noticed. In all cases, acute urinary retention was transient and treated with temporary intermittent self-catheterization. There was no statistically significant correlation between dosage and observed side effects. Patients' satisfaction rate was high (71.4%).
CONCLUSION: Intradetrusor injection of botulinum toxin was associated with a high rate of neurourological side effects. In general, side effects were transient, mild and did not require special treatment.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20639617     DOI: 10.1159/000316080

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

Review 1.  Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults.

Authors:  Douglas G Tincello
Journal:  World J Urol       Date:  2011-10-15       Impact factor: 4.226

2.  Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB.

Authors:  Linda Brubaker; Angelo Gousse; Peter Sand; Catherine Thompson; Vaishali Patel; Jihao Zhou; Brenda Jenkins; Karl-Dietrich Sievert
Journal:  Int Urogynecol J       Date:  2012-01-25       Impact factor: 2.894

3.  Patient preferences for treating refractory overactive bladder in the UK.

Authors:  Hashim Hashim; Kathleen Beusterien; John F P Bridges; Kaitlan Amos; Linda Cardozo
Journal:  Int Urol Nephrol       Date:  2015-09-07       Impact factor: 2.370

4.  OnabotulinumtoxinA in the treatment of neurogenic bladder.

Authors:  Aziz Gulamhusein; Altaf Mangera
Journal:  Biologics       Date:  2012-08-28

5.  Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.

Authors:  Osama Abdelwahab; Hammouda Sherif; Tark Soliman; Ihab Elbarky; Aly Eshazly
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

6.  Bladder diverticuli following injection of onabotulinum toxin A in a patient with multiple sclerosis and autosomal dominant polycystic kidney disease.

Authors:  Syed Imran Raza; Ashkan Heshmatzadeh Behzadi; Jon D Blumenfeld; Sarah K Girardi; Martin R Prince
Journal:  Radiol Case Rep       Date:  2018-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.